Antibody drugs and cell therapies are at the heart of new biotechnology science. Not only do they show great promise when it comes to curing disease and helping patients, but also in creating value and growth. Biotech companies need to protect their scientific results and the corresponding investments with strong and durable patents. This is a complex task, with constantly evolving case law and practice on both sides of the Atlantic. In this webinar, AWA’s experts focus on how to create, defend and litigate these patents in Europe and elsewhere.
Patenting Antibody and Cell Therapies – What to Do and What Not to Do
You may also be interested in:
Patents and Intellectual Property – Strategic Aspects
As part of Redeye’s ProView series, Jessica Martinsson, COO of Sprint Bioscience joins European patent attorneys Joanna Applequist and
Is 1 April 2023 the date for entry into force of the Unitary Patent?
On 6 October, the UPC Preparatory team published information that they are currently planning for entry into force of
CJEU clarifies protected designations of origin in Danish Feta case
A recent judgment from the Court of Justice of the European Union has clarified the extent of protection for